Search research articles
Contact Us
Filters
Showing results (151-160 of 190) with videos related to
Page
of 19
Sort By:
Nature Communications
|
May 3, 2020
Effective combinatorial immunotherapy for penile squamous cell carcinoma
Tianhe Huang, Xi Cheng, Jad Chahoud, et al.
Nature
|
February 7, 2017
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Di Zhao, Xin Lu, Guocan Wang, et al.
Nature Genetics
|
September 18, 2024
Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity
Ateeq M Khaliq, Meenakshi Rajamohan, Omer Saeed, et al.
Cancer Cell
|
May 19, 2010
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas
Hongwu Zheng, Haoqiang Ying, Ruprecht Wiedemeyer, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 15, 2009
Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo
Ny Sin, Brian L Venables, Keith D Combrink, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 22, 2005
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo
Kuo-Long Yu, Xiangdong Alan Wang, Rita L Civiello, et al.
Nature
|
July 9, 2015
Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer
Florian Muller, Simona Colla, Elisa Aquilanti, et al.
Cancers
|
July 24, 2021
Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer
Delphine Dayde, Jillian Gunther, Yutaka Hirayama, et al.
Nature Chemical Biology
|
October 11, 2016
SF2312 is a natural phosphonate inhibitor of enolase
Paul G Leonard, Nikunj Satani, David Maxwell, et al.
Antimicrobial Agents and Chemotherapy
|
January 27, 2004
Orally active fusion inhibitor of respiratory syncytial virus
Christopher Cianci, Kuo-Long Yu, Keith Combrink, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 190) with videos related to
Sort By:
Page
of 19
Nature Communications
|
May 3, 2020
Effective combinatorial immunotherapy for penile squamous cell carcinoma
Tianhe Huang, Xi Cheng, Jad Chahoud, et al.
Nature
|
February 7, 2017
Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Di Zhao, Xin Lu, Guocan Wang, et al.
Nature Genetics
|
September 18, 2024
Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity
Ateeq M Khaliq, Meenakshi Rajamohan, Omer Saeed, et al.
Cancer Cell
|
May 19, 2010
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas
Hongwu Zheng, Haoqiang Ying, Ruprecht Wiedemeyer, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 15, 2009
Respiratory syncytial virus fusion inhibitors. Part 7: structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo
Ny Sin, Brian L Venables, Keith D Combrink, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 22, 2005
Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo
Kuo-Long Yu, Xiangdong Alan Wang, Rita L Civiello, et al.
Nature
|
July 9, 2015
Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer
Florian Muller, Simona Colla, Elisa Aquilanti, et al.
Cancers
|
July 24, 2021
Identification of Blood-Based Biomarkers for the Prediction of the Response to Neoadjuvant Chemoradiation in Rectal Cancer
Delphine Dayde, Jillian Gunther, Yutaka Hirayama, et al.
Nature Chemical Biology
|
October 11, 2016
SF2312 is a natural phosphonate inhibitor of enolase
Paul G Leonard, Nikunj Satani, David Maxwell, et al.
Antimicrobial Agents and Chemotherapy
|
January 27, 2004
Orally active fusion inhibitor of respiratory syncytial virus
Christopher Cianci, Kuo-Long Yu, Keith Combrink, et al.
Page
of 19